论文部分内容阅读
近年来,随着细胞生物学和分子生物学的飞速发展,生物治疗已成为继手术、化疗和放疗三大常规治疗之后的第四种肿瘤治疗模式。为进一步推动肿瘤生物治疗临床与基础研究,受《中国肿瘤临床》之邀,开辟肿瘤生物治疗专栏,与广大读者共享国内外肿瘤生物治疗的最新研究成果。专栏特邀美国Moffitt肿瘤中心教授、Donald A.Adam黑色素瘤研究中心主任Jeffrey S.Weber博士介绍了恶性黑色素瘤生物治疗领域的最新进展。还邀请中国医学科学院肿瘤医院肿瘤研究所免疫室主任张叔人教授对新版《药品生产质量管理规范》进行解读,强调了体细胞治疗质控的重要性。以及天津医科大学附属肿瘤医院生物治疗中心在细胞免疫生物治疗方面获得的一些经验供广大同道讨论和借鉴。
In recent years, with the rapid development of cell biology and molecular biology, biological therapy has become the fourth tumor treatment mode following the three conventional treatments of surgery, chemotherapy and radiotherapy. In order to further promote the clinical and basic research of tumor biotherapy, by the invitation of “Cancer Oncology in China”, we open up the column of cancer biotherapy and share the latest research results of cancer biotherapy at home and abroad with the readers. Column Invited Dr. Moffitt Cancer Center, Donald A.Adam, director of Melanoma Research Center, Dr. Jeffrey S.Weber introduced the latest advances in the field of biomedical therapy of malignant melanoma. Professor Zhang Shuren, director of the immunization room at the Cancer Institute Cancer Institute of Chinese Academy of Medical Sciences, was also invited to interpret the new “Code of Practice for the Quality of Pharmaceutical Production”, emphasizing the importance of quality control of somatic cell therapy. And Tianjin Medical University Cancer Hospital Cancer Center biological treatment center in the biological immune cell therapy for some of the experience for the majority of fellow discussion and reference.